Immuron Ltd Files 6-K Report

TL;DR

Immuron Ltd filed a 6-K on July 2nd, just a routine update for investors.

AI Summary

Immuron Limited filed a Form 6-K on July 2, 2024, reporting its activities for the month of July 2024. The filing indicates that the company is a foreign private issuer and is not furnishing information under Rule 12g3-2(b). The report is filed under the 1934 Act.

Why It Matters

This filing provides an update on Immuron Limited's regulatory disclosures, which is important for investors tracking the company's compliance and reporting status.

Risk Assessment

Risk Level: low — This filing is a standard regulatory report and does not contain new financial or operational information that would typically indicate a change in risk.

Key Players & Entities

• Immuron Limited (company) — Registrant
• 001-38104 (company) — Commission File Number
• July 2, 2024 (date) — Filing Date

FAQ

Filing Documents

• ea0208866-6k_immuron.htm (6-K) — 13KB
• ea020886601ex99-1_immuron.htm (EX-99.1) — 16KB
• ex99-1_001.jpg (GRAPHIC) — 5KB
• ex99-1_002.jpg (GRAPHIC) — 82KB
• ex99-1_003.jpg (GRAPHIC) — 3KB
• ex99-1_004.jpg (GRAPHIC) — 7KB
• 0001213900-24-058180.txt ( ) — 164KB

From the Filing

OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes No If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- IMMURON LIMITED EXPLANATORY NOTE Immuron Limited (the “Company”) published one announcement (the “Public Notices”) to the Australian Securities Exchange on July 2, 2024 titled: - “IMM-529 pre-IND FDA filing” A copy of the Public Notice is attached as an exhibit to this report on Form 6-K. This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. 1 EXHIBITS Exhibit Number Description 99.1 IMM-529 pre-IND FDA filing 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMURON LIMITED Date: July 2, 2024 By: /s/ Phillip Hains Phillip Hains Company Secretary 3

View Full Filing

View this 6-K filing on SEC EDGAR